Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia

17 Feb 2006

Abstract excerpt

Recent insights into the molecular mechanisms of polycythemia vera (PV) and essential thrombocythemia (ET) are challenging the traditional diagnostic classification of these myeloproliferative disorders (MPDs). Clonality analysis using X-chromosome inactivation patterns has revealed apparent heterogeneity among the MPDs. The recently discovered single somatic activating point mutation in the JAK2 gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16484586
DOI: 10.1182/blood-2005-08-3526

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemiaPMID 16484586Read ↗

Management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.Semantic proximity Read ↗

Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision MedicineSemantic proximity Read ↗

Polycythaemia vera: molecular genetics, diagnostics and therapeutics.Semantic proximity Read ↗

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.